InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.248 (-95.38%)+
Announcement
Release
17 Jun 2026 12:05PM
Price at Release
$0.260
Full Release
download
Summary
Cynata Therapeutics Limited announced the primary evaluation results of the Phase 2 clinical trial of CYP-001 for treating high-risk acute graft versus host disease (HR-aGvHD). The trial enrolled 65 patients across clinical centers in Australia, the USA, and Europe. Patients were randomized to receive either steroids plus CYP-001 or steroids plus placebo. The trial's primary evaluation period of 100 days showed no significant differences in primary or key secondary endpoints between the groups. As a result, the company decided to terminate the trial early due to the underwhelming results compared to the promising Phase 1 results. The company expressed disappointment and acknowledged the contributions of personnel and patients involved in the trial. Cynata is awaiting results from the Phase 3 SCUlpTOR trial for CYP-004 in osteoarthritis, expected soon.
Key Points
  • CYP-001 Phase 2 trial for HR-aGvHD had no safety concerns.
  • No significant endpoint differences between groups.
  • Trial terminated early due to unsatisfactory results.
  • Cynata remains under ASX suspension, awaiting CYP-004 trial results.
  • Acknowledgement of contributions from trial participants and staff.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.